Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Pediatric Patients With Cystic Fibrosis Lung Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Denufosol (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 30 May 2014 New trial record